IBUPROHM COLD AND SINUS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IBUPROHM COLD AND SINUS (IBUPROHM COLD AND SINUS).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
| Metabolism | Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation and is excreted largely unchanged in urine. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%. |
| Half-life | 1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance. |
| Protein binding | Ibuprofen: 99% bound to albumin; pseudoephedrine: 20–30% bound to plasma proteins. |
| Volume of Distribution | 0.1–0.2 L/kg for ibuprofen, indicating limited distribution to tissues; pseudoephedrine Vd is approximately 2.6–3.3 L/kg. |
| Bioavailability | Oral (immediate-release): >80% absorbed; nasal spray: approximately 70% (relative to oral). |
| Onset of Action | Oral: 30–60 minutes for analgesic effect; intranasal: 15–30 minutes. |
| Duration of Action | 4–6 hours for analgesia and antipyresis; decongestant (pseudoephedrine) effect lasts 4–6 hours as well. |
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 50% and monitor renal function; eGFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated. |
| Pediatric use | For children ≥12 years: same as adult dosing; for children <12 years: not recommended due to pseudoephedrine component. |
| Geriatric use | Start at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure; maximum daily dose: 4 tablets (ibuprofen 800 mg, pseudoephedrine 120 mg). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IBUPROHM COLD AND SINUS (IBUPROHM COLD AND SINUS).
| Breastfeeding | Ibuprofen is considered compatible with breastfeeding; M/P ratio is approximately 0.6-0.9 with low infant exposure. Pseudoephedrine is excreted into breast milk with M/P ratio about 2-3; it may cause irritability in infants and reduce milk production due to vasoconstriction. Combination product use is not recommended during lactation. |
| Teratogenic Risk | Ibuprofen is contraindicated in the third trimester due to risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. In the first and second trimesters, use is generally avoided unless necessary; risks include miscarriage and congenital malformations, though data are conflicting. Pseudoephedrine is teratogenic in animal studies at high doses; human data show possible association with gastroschisis in first trimester. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Also, NSAIDs can increase risk of cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal.
| Serious Effects |
["Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the product","History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs","During perioperative pain in the setting of coronary artery bypass graft (CABG) surgery","Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy","Severe hypertension or coronary artery disease","Pregnancy (especially third trimester) and breastfeeding"]
| Precautions | ["Cardiovascular thrombotic events","Gastrointestinal bleeding, ulceration, and perforation","Hypertension and exacerbation of hypertension","Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome)","Renal toxicity","Hepatic effects","Anaphylactoid reactions","Avoid in patients with aspirin-sensitive asthma"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and evidence of premature labor. Fetal ultrasound for amniotic fluid index and ductus arteriosus patency if used in third trimester. Assess for signs of infant irritability or sedation if used near delivery. |
| Fertility Effects | Ibuprofen may impair fertility in women by interfering with prostaglandin synthesis affecting ovulation and implantation; effects are reversible upon discontinuation. Pseudoephedrine has no known direct effect on fertility. |